Repligen (RGEN) PT Raised to $175 at Barclays
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $165.70 +0.56%
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Join SI Premium – FREE
Barclays analyst Luke Sergott raised the price target on Repligen (NASDAQ: RGEN) to $175.00 (from $160.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Monopar Therapeutics (MNPR) PT Raised to $133 at BTIG
- Toei co Ltd (9605:JP) PT Raised to JPY6,100 at Nomura/Instinet
- Riskified Ltd. (RSKD) PT Raised to $5.50 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
